ORGANIZATION

• Regional Formularies Seen Driving Shift to Quality, Industry Consolidation: Society Head
  April 27, 2026

• JPMA Mulls Proposal to Standardize PMDA Review Reports
  April 27, 2026

• JPWA Urges Caution on Fixed Margins, Citing French Model Shortcomings
  April 24, 2026

• APAC Disbands Drug Discovery WG as Asia Capabilities Rise
  April 23, 2026

• Flight Cuts, Fuel Costs Tied to Iran Crisis Threaten API Imports: Trader
  April 23, 2026

• JPMA to Set Up Task Force on US MFN Policy, First Meeting Seen This Month
  April 21, 2026

• PhRMA Warns Japan Launches Could Erode Global Revenues amid US MFN Policy
  April 20, 2026

• JPMA Exec Frets over Material Cost Surge amid Middle East Crisis
  April 17, 2026

• JPMA Reshaping Organization to Boost Agility as It Shifts to Legal Entity
  April 16, 2026

• JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
  April 15, 2026

• Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
  April 8, 2026

• Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
  April 8, 2026

• Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
  April 7, 2026

• Generic Use Rate Hits 90% for First Time in October-December: JGA
  April 7, 2026

• JPMA to Prepare Response to US “MFN” Policy under New Strategy Unit
  April 2, 2026

• Five Groups Urge Action to Secure Medical Supplies amid Iran War
  April 2, 2026

• JPMA Unveils Committee Action Plans, Prioritizes Innovation-Focused Drug Pricing
  April 2, 2026

• UCB’s Kikuchi Appointed EFPIA Japan Vice Chair
  April 2, 2026

• JMA’s Ezawa Calls for “National Debate” on Drug Policy
  March 31, 2026

• BCG’s Takeda Questions Conditional Pricing for Regenerative Medicines
  March 25, 2026

ページ

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• …
• Next ›
• 最終 »